ESR1 and breast carcinoma: Unfortunately, there is a wide range of doses reported in the literature, for example, a delay in tumor development in a mouse lung cancer model mentioned with 10 mg/kg [25]; 25 mg/kg in breast cancer-positive to Estrogen Receptors [26] and in leukemia [27]; 30 mg/kg in osteosarcoma [28]; 50 mg/kg in triple negative breast [29]; 57 mg/kg in prostate carcinoma [30]; an effect has even been observed with doses as high as 100 mg/kg, as happened in bladder cancer where the tumor was reduced by 63% [31].